Cargando…

A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma

The efficacy of anti‐angiogenic treatment by targeting VEGF/VEGF receptors in metastatic clear cell renal cell carcinoma (ccRCC) varies from patient to patient. Discovering the reasons behind this variability could lead to the identification of relevant therapeutic targets. Thus, we investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montemagno, Christopher, Durivault, Jérôme, Gastaldi, Cécile, Dufies, Maeva, Vial, Valérie, He, Xingkang, Ambrosetti, Damien, Kamenskaya, Anna, Negrier, Sylvie, Bernhard, Jean‐Christophe, Borchiellini, Delphine, Cao, Yihai, Pagès, Gilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323879/ https://www.ncbi.nlm.nih.gov/pubmed/36810959 http://dx.doi.org/10.1002/1878-0261.13401

Ejemplares similares

Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
por: Montemagno, Christopher, et al.
Publicado: (2020)

In vivo monitoring of the therapeutic efficacy of a CXCR1/2 inhibitor with 18F-FDG PET/CT imaging in experimental head and neck carcinoma: A feasibility study
por: Montemagno, Christopher, et al.
Publicado: (2021)

Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma
por: Hagege, Anais, et al.
Publicado: (2022)

Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies
por: Guyot, Mélanie, et al.
Publicado: (2016)

The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy
por: Hagege, Anais, et al.
Publicado: (2021)

The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma
por: Ambrosetti, Damien, et al.
Publicado: (2018)

VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness
por: Ndiaye, Papa Diogop, et al.
Publicado: (2019)

Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma
por: Dufies, Maeva, et al.
Publicado: (2021)

Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma
por: Dufies, Maeva, et al.
Publicado: (2018)

Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
por: Montemagno, Christopher, et al.
Publicado: (2021)

Experimental Models in Neovascular Age Related Macular Degeneration
por: Rastoin, Olivia, et al.
Publicado: (2020)

Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5
por: Giuliano, Sandy, et al.
Publicado: (2019)

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
por: Dufies, Maeva, et al.
Publicado: (2017)

Anti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell Carcinomas
por: Dumond, Aurore, et al.
Publicado: (2021)

The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor
por: Grépin, Renaud, et al.
Publicado: (2020)

Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma
por: Pagnuzzi-Boncompagni, Marina, et al.
Publicado: (2021)

The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma
por: Polena, Helena, et al.
Publicado: (2018)

AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity
por: Brolih, Sanja, et al.
Publicado: (2018)

Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression
por: Cooley, Lindsay S., et al.
Publicado: (2021)

Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma
por: Dumond, Aurore, et al.
Publicado: (2021)

VEGF Spliced Variants: Possible Role of Anti-Angiogenesis Therapy
por: Hilmi, Caroline, et al.
Publicado: (2012)

LC-MS based metabolomic profiling for renal cell carcinoma histologic subtypes
por: Jing, Lun, et al.
Publicado: (2019)

SH3BGRL2, a new downregulated tumor suppressor in clear cell renal cell carcinomas
por: Dufies, Maeva
Publicado: (2020)

New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments
por: Dufies, Maeva, et al.
Publicado: (2019)

Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs
por: Montemagno, Christopher, et al.
Publicado: (2020)

Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine
por: Montemagno, Christopher, et al.
Publicado: (2020)

ATP-competitive Plk1 inhibitors induce caspase 3-mediated Plk1 cleavage and activation in hematopoietic cell lines
por: Dufies, Maeva, et al.
Publicado: (2017)

Identification of a new aggressive axis driven by ciliogenesis and absence of VDAC1-ΔC in clear cell Renal Cell Carcinoma patients
por: Fabbri, Lucilla, et al.
Publicado: (2020)

The impact of the hypoxia‐VEGF‐vascular permeability on COVID‐19‐infected patients
por: Cao, Yihai
Publicado: (2021)

In Vivo Assessment of VCAM-1 Expression by SPECT/CT Imaging in Mice Models of Human Triple Negative Breast Cancer
por: Montemagno, Christopher, et al.
Publicado: (2019)

Tumor-derived VEGF modulates hematopoiesis
por: Xue, Yuan, et al.
Publicado: (2009)

The Relevance of Testing the Efficacy of Anti-Angiogenesis Treatments on Cells Derived from Primary Tumors: A New Method for the Personalized Treatment of Renal Cell Carcinoma
por: Grépin, Renaud, et al.
Publicado: (2014)

From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma
por: Montemagno, Christopher, et al.
Publicado: (2020)

Role of alternative splicing of VEGF-A in the development of atherosclerosis
por: Zhao, Naishi, et al.
Publicado: (2018)

Disrupting glucose-6-phosphate isomerase fully suppresses the “Warburg effect” and activates OXPHOS with minimal impact on tumor growth except in hypoxia
por: de Padua, Monique Cunha, et al.
Publicado: (2017)

Targeting of the ELR+CXCL/CXCR1/2 Pathway Is a Relevant Strategy for the Treatment of Paediatric Medulloblastomas
por: Penco-Campillo, Manon, et al.
Publicado: (2022)

New Phenylspirodrimanes from the Sponge-Associated Fungus Stachybotrys chartarum MUT 3308
por: Dayras, Marie, et al.
Publicado: (2023)

Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors
por: Hosaka, Kayoko, et al.
Publicado: (2020)

The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5)
por: Cormerais, Yann, et al.
Publicado: (2018)

Microenvironment Changes (in pH) Affect VEGF Alternative Splicing
por: Elias, Ana Paula, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_77s2mai6trrq4ptckgcdbjrdoc